Aligos Therapeutics (ALGS) Stock
Clinical stage biotech developing liver and viral treatments. Here's the price, business snapshot, and what's worth knowing about Aligos Therapeutics in August 2026.
Aligos Therapeutics (ALGS) is a clinical-stage biotechnology company developing therapies focused on liver and viral diseases, notably programmes addressing chronic hepatitis B and related conditions. As a small-cap, research-led company (market cap around $64.5m), its value is driven largely by clinical trial progress, regulatory milestones and potential partnerships or licensing deals rather than current revenue. Investors should expect high volatility and binary outcomes: positive clinical data or approvals can materially re-rate the stock, while setbacks can lead to sharp declines. Common risks include lengthy development timelines, regulatory uncertainty and the potential need to raise capital, which can dilute shareholders. For those tracking ALGS, keep an eye on trial readouts, pipeline updates, cash runway and collaboration announcements. This information is general and educational, not personalised investment advice — potential investors should consider their risk tolerance and seek independent financial advice where appropriate.
About This Stock
ALIGOS THERAPEUTICS INC
ALGS
Current Price
$6.96
Potential 12 Month Profit
1,256.78%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Ticker
ALGS
Market Cap
$43.02M
Potential 12 Month Profit
1,256.78%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Aligos Therapeutics' stock with a target price of $65, indicating strong growth potential.
Financial Health
Aligos Therapeutics is managing cash and revenue reasonably well, but growth potential appears limited.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Why You’ll Want to Watch This Stock
Clinical-stage drug programmes
Pipeline progress and trial readouts drive value, so milestones can create strong share movements — though outcomes can be binary and unpredictable.
Upcoming catalysts and milestones
Regulatory decisions, trial data and partnership news are likely catalysts to watch; these events can lead to rapid gains or losses.
Cash position and dilution
As a small-cap biotech, monitoring cash runway and fundraising plans is important because additional capital raises can dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.